They are:
- Eylea (Regeneron) — $2.58 billion
- Keytruda (Merck) — $1.81 billion
- Opdivo (Bristol Myers Squibb) — $1.72 billion
- Rituxan (Roche) — $1.70 billion
- Prolia/Xgeva (Amgen) — $1.42 billion
- Neulasta (Amgen) — $1.37 billion
- Lucentis (Genentech) — $1.22 billion
- Remicade (J&J) — $1.15 billion
- Avastin (Genentech) — $1.01 billion
- Herceptin (Genentech) — $823 million
More articles on pharmacy:
Ohio pharmacy board reverses hydroxychloroquine ban
US to pay Sanofi, GlaxoSmithKline up to $2.1B for development, 100M doses of coronavirus vaccine
25% of diabetes patients rationing treatments amid pandemic, survey finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
